The Anti-ENA Panel (Extractable Nuclear Antigen Antibodies Panel) is a specialized blood test used to detect autoantibodies against specific proteins found in the cell nucleus, known as extractable nuclear antigens (ENAs). This test is particularly valuable in the diagnosis and differentiation of autoimmune diseases such as Systemic Lupus Erythematosus (SLE), Sjögren’s Syndrome, Scleroderma, Polymyositis, and Mixed Connective Tissue Disease (MCTD).
The ENA panel typically includes specific antibodies such as:
Anti-Sm (highly specific for lupus),
Anti-RNP (associated with MCTD),
Anti-SSA/Ro and Anti-SSB/La (linked to Sjögren’s syndrome and lupus),
Anti-Scl-70 (associated with scleroderma),
Anti-Jo-1 (linked to polymyositis/dermatomyositis).
This test is often performed after a positive ANA (antinuclear antibody) test to help identify the exact type of autoantibody and underlying autoimmune condition. Diagnostic methods typically include ELISA (Enzyme-Linked Immunosorbent Assay) or immunoblot techniques.
A positive result for any of these antibodies can assist in diagnosing specific diseases. For example, anti-Sm is a specific marker for lupus, whereas anti-Scl-70 is predictive of skin fibrosis in scleroderma. However, interpretation of results must be made in the context of clinical symptoms, patient history, and other laboratory findings (such as ANA and anti-dsDNA), as some antibodies may be present in multiple overlapping diseases.
The Anti-ENA panel plays a key role in accurate diagnosis, predicting disease course, and guiding targeted treatment planning in rheumatology.
